MCID: BRD004
MIFTS: 51

Borderline Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

MalaCards integrated aliases for Borderline Personality Disorder:

Name: Borderline Personality Disorder 12 75 55 44 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:10930
ICD9CM 35 301.83
MeSH 44 D001883
NCIt 50 C92633
SNOMED-CT 68 20010003
ICD10 33 F60.3
UMLS 72 C0006012

Summaries for Borderline Personality Disorder

Disease Ontology : 12 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary : Borderline Personality Disorder is related to avoidant personality disorder and alexithymia. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Citalopram and Lamotrigine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and amygdala, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 75 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder (EUPD),... more...

Related Diseases for Borderline Personality Disorder

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 207)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 32.2 TPH1 SLC6A4 MAOA
2 alexithymia 31.1 SLC6A4 HTR1A COMT
3 dysthymic disorder 31.0 SLC6A4 MAOA HTR2A
4 antisocial personality disorder 30.8 SLC6A4 MAOA HTR1B COMT
5 eating disorder 30.8 SLC6A4 HTR2C COMT BDNF
6 traumatic brain injury 30.7 COMT BDNF
7 conduct disorder 30.7 TPH1 SLC6A4 MAOA COMT
8 oppositional defiant disorder 30.6 SLC6A4 MAOA COMT
9 agoraphobia 30.6 SLC6A4 MAOA HTR1A
10 phobia, specific 30.6 MAOA COMT
11 intermittent explosive disorder 30.5 SLC6A4 PRL HTR1A
12 substance dependence 30.4 SLC6A4 MAOA HTR1B BDNF
13 atypical depressive disorder 30.4 SLC6A4 MAOA HTR2A
14 schizophreniform disorder 30.4 PRL COMT
15 bipolar disorder 30.3 TPH1 SLC6A4 HTR2A HTR1A COMT BDNF
16 social phobia 30.3 SLC6A4 PRL MAOA HTR1A
17 bulimia nervosa 30.2 SLC6A4 HTR2A HTR1B COMT BDNF
18 substance abuse 30.2 SLC6A4 PRL MAOA HTR1B COMT BDNF
19 tardive dyskinesia 30.2 HTR2A COMT
20 anorexia nervosa 30.2 SLC6A4 PRL HTR2A COMT BDNF
21 substance-induced psychosis 30.2 HTR2A HTR1A
22 sexual disorder 30.2 SLC6A4 PRL HTR1A
23 fibromyalgia 30.2 SLC6A4 PRL HTR2A COMT
24 amnestic disorder 30.2 HTR1A BDNF
25 paraphilia disorder 30.0 PRL MAOA
26 schizoaffective disorder 30.0 SLC6A4 PRL HTR2A COMT BDNF
27 panic disorder 29.9 SLC6A4 MAOA HTR2A HTR1A COMT
28 tobacco addiction 29.7 TPH1 SLC6A4 MAOA HTR2A COMT
29 autism spectrum disorder 29.5 SLC6A4 HTR2A BDNF AVPR1A
30 postpartum depression 29.4 SLC6A4 PRL MAOA COMT BDNF
31 paranoid schizophrenia 29.2 SLC6A4 MAOA HTR2A COMT BDNF
32 autism 29.1 SLC6A4 HTR2A HTR1A BDNF AVPR1A
33 generalized anxiety disorder 29.1 TPH1 SLC6A4 MAOA HTR2A HTR1A COMT
34 bipolar i disorder 29.0 SLC6A4 HTR2C HTR2A HTR1A COMT BDNF
35 psychotic disorder 28.6 TPH1 SLC6A4 PRL HTR2C HTR2A HTR1A
36 disease of mental health 28.6 SLC6A4 MAOA HTR2C HTR2A HTR1A COMT
37 post-traumatic stress disorder 28.6 SLC6A4 NR3C1 MAOA HTR2A FKBP5 COMT
38 depression 28.4 TPH1 SLC6A4 NR3C1 MAOA HTR2C HTR2A
39 personality disorder 28.4 TPH1 SLC6A4 PRL MAOA HTR2C HTR2A
40 endogenous depression 28.2 TPH1 SLC6A4 NR3C1 MAOA HTR2A HTR1A
41 attention deficit-hyperactivity disorder 28.2 TPH1 SLC6A4 MAOA HTR2C HTR2A HTR1B
42 chronic fatigue syndrome 27.9 SLC6A4 NR3C1 MAOA HTR2A HTR1A COMT
43 alcohol dependence 27.7 TPH1 SLC6A4 MAOA HTR2C HTR2A HTR1B
44 anxiety 27.6 TPH1 SLC6A4 NR3C1 MAOA HTR2C HTR2A
45 obsessive-compulsive disorder 27.2 TPH1 SLC6A4 PRL MAOA HTR2C HTR2A
46 mental depression 27.2 TPH1 SLC6A4 NR3C1 MAOA HTR2C HTR2A
47 migraine with or without aura 1 27.2 TPH1 SLC6A4 MAOA HTR2C HTR2A HTR1B
48 mood disorder 27.0 TPH1 SLC6A4 NR3C1 MAOA HTR2C HTR2A
49 schizophrenia 26.9 TPH1 SLC6A4 PRL MAOA HTR2C HTR2A
50 major depressive disorder 26.1 TPH1 SLC6A4 PRL NR3C1 MAOA HTR2C

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Cerebral Atherosclerosis Dependent Personality Disorder
Dysthymic Disorder Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to Borderline Personality Disorder

Symptoms & Phenotypes for Borderline Personality Disorder

MGI Mouse Phenotypes related to Borderline Personality Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 AVPR1A BDNF COMT FKBP5 HTR1A HTR1B
2 homeostasis/metabolism MP:0005376 10 AVPR1A BDNF COMT FKBP5 HTR1A HTR2C
3 cardiovascular system MP:0005385 9.97 AVPR1A COMT HTR1A HTR1B MAOA NR3C1
4 endocrine/exocrine gland MP:0005379 9.92 AVPR1A BDNF COMT HTR1B HTR2A NR3C1
5 integument MP:0010771 9.63 BDNF HTR2C NR3C1 PRL SLC6A4 TPH1
6 muscle MP:0005369 9.5 AVPR1A HTR1B HTR2A HTR2C NR3C1 SLC6A4
7 nervous system MP:0003631 9.28 AVPR1A BDNF COMT HTR1A HTR2C MAOA

Drugs & Therapeutics for Borderline Personality Disorder

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4 59729-33-8 2771
2
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
7 Omega 3 Fatty Acid Phase 4
8 Neurotransmitter Agents Phase 4
9 Serotonin Uptake Inhibitors Phase 4
10 Peripheral Nervous System Agents Phase 4
11 Neurotransmitter Uptake Inhibitors Phase 4
12 Serotonin Agents Phase 4
13 Autonomic Agents Phase 4
14 Parasympatholytics Phase 4
15 Antidepressive Agents Phase 4
16 Antidepressive Agents, Second-Generation Phase 4
17 Cholinergic Agents Phase 4
18 Muscarinic Antagonists Phase 4
19 Cholinergic Antagonists Phase 4
20 Antiparkinson Agents Phase 4
21 Diuretics, Potassium Sparing Phase 4
22 Sodium Channel Blockers Phase 4
23 Calcium, Dietary Phase 4
24 calcium channel blockers Phase 4
25 Dopamine Agents Phase 4
26 Serotonin Antagonists Phase 4
27 Dopamine Antagonists Phase 4
28 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
29 Cytochrome P-450 Enzyme Inhibitors Phase 4
30
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
31
Rifaximin Approved, Investigational Phase 2, Phase 3 80621-81-4 46783403 6436173
32
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
33
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 5195 26757
34
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
35 Sulfalene Phase 2, Phase 3
36 Antibiotics, Antitubercular Phase 2, Phase 3
37 Antitubercular Agents Phase 2, Phase 3
38 Anti-Bacterial Agents Phase 2, Phase 3
39 Antiemetics Phase 3
40 Gastrointestinal Agents Phase 3
41 Tranquilizing Agents Phase 3
42 Quetiapine Fumarate Phase 3 111974-72-2
43 Narcotics Phase 3
44 Narcotic Antagonists Phase 3
45 Analgesics, Opioid Phase 3
46
Acetaminophen Approved Phase 2 103-90-2 1983
47
Ziprasidone Approved Phase 2 146939-27-7 60854
48
Lithium carbonate Approved Phase 2 554-13-2
49
Cocaine Approved, Illicit Phase 2 50-36-2 446220 5760
50
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758

Interventional clinical trials:

(show top 50) (show all 169)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
3 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS) Completed NCT00204347 Phase 4 risperidone
4 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
5 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
6 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
7 Effect of Probiotics on Central Nervous System Functions in Humans Unknown status NCT02793193 Phase 2, Phase 3 Antibiotic
8 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo Completed NCT00088036 Phase 3 Olanzapine
9 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo Completed NCT00091650 Phase 3 Olanzapine;placebo
10 BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder Completed NCT00538135 Phase 3
11 A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
12 Seroquel XR for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
13 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
14 Short-term Versus Long-term Mentalization-based Therapy for Outpatients With Subthreshold or Diagnosed Borderline Personality Disorder: a Randomized Clinical Trial Recruiting NCT03677037 Phase 3
15 Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder Terminated NCT00124839 Phase 3 Naltrexone
16 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3 Topiramate
17 Acetaminophen and Social Pain in Borderline Personality Disorder Unknown status NCT02108990 Phase 2 Acetaminophen
18 The Efficacy of a Cognitive-Behavioural Intervention in Deliberate Self-Harm Patients: A Randomized Controlled Trial Among Adolescents and Young Adults Unknown status NCT00169884 Phase 2
19 Pilot Study of Central Meditation and Imagery Therapy for Borderline Personality Disorder Completed NCT02125942 Phase 1, Phase 2
20 The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial Completed NCT00254748 Phase 2 Quetiapine fumarate;Placebo
21 Assessment and Treatment of Parasuicidal Patients Completed NCT00183651 Phase 2
22 Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study Completed NCT00635921 Phase 2 ziprasidone;Placebo
23 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2 Naltrexone;Placebo
24 Psychodynamic Therapy for Patients With Borderline Personality Disorder and Alcohol Abuse Completed NCT00145678 Phase 2
25 Treating PTSD in Patients With Borderline Personality Disorder Completed NCT01081314 Phase 1, Phase 2
26 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
27 Cognitive Behavioral Therapy for PTSD in Addiction Treatment: A Randomized Pilot Trial Completed NCT01456338 Phase 2
28 Cognitive Therapy for PTSD in Addiction Treatment Completed NCT00685451 Phase 1, Phase 2
29 The Use of Oxytocin as Adjunctive Therapy for the Treatment of Schizophrenia: a Randomized, Double Blind Trial Completed NCT01699997 Phase 2 Oxytocin;Placebo
30 Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) Recruiting NCT02728778 Phase 2 incobotulinumtoxin A
31 A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder. Recruiting NCT03418675 Phase 2 Rexulti;Placebo
32 A Randomised Double-blind Placebo Controlled Investigation of the Efficacy of a Novel Drug as an Adjunct in Patients With Borderline Personality Disorder Recruiting NCT02097706 Phase 2 NMDA receptor antagonist (active drug)
33 A Randomized Active Placebo Controlled Trial of Ketamine in Borderline Personality Disorder Recruiting NCT03395314 Phase 2 Ketamine;Midazolam
34 Dialectical Behavior Therapy (DBT) for Adolescents With Bipolar Disorder Recruiting NCT02003690 Phase 2 Pharmacotherapy
35 Investigating the Impact of Oxytocin on Irritability/Emotional Dysregulation in Children and Adolescents With Disruptive Behavior and Mood Disorders, and the Possible Mediating Role of Amygdala Activity Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
36 Multimodal Study of the Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder : Stress Reactivity and Functional Imaging Not yet recruiting NCT03209102 Phase 2
37 SSRIs and Self-harm in Borderline Personality Disorder Terminated NCT01103180 Phase 2 Escitalopram
38 Preliminary, Double Blind, Placebo Controlled Trial of the Effect of Glucocorticoid Receptor Antagonist Treatment on Biologic and Symptom Outcomes in Patients With Borderline Personality Disorder and Histories of Childhood Abuse Terminated NCT01212588 Phase 2 mifepristone;Placebo
39 A Double-Blind, Placebo-controlled Pilot Study of NAC Addition to Dialectical Behavioral Therapy for the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder Terminated NCT00539188 Phase 2 N-Acetylcysteine;placebo
40 Creativity Group for Borderline Personality Disorder Unknown status NCT01343550 Phase 1
41 Study of Outcome With an Intervention From the Cape Cod Model of Psychotherapy for Subjects in a Behavioral Crisis and With the Diagnosis of Borderline Personality Disorder (BPD) or Post-Traumatic Stress Disorder (PTSD) Unknown status NCT00269139 Phase 1
42 Evaluating the Effectiveness of Dialectical Behaviour Skills Training for Suicidality in Borderline Personality Disorder Completed NCT01193205 Phase 1
43 N-Acetylcysteine in the Treatment of Deliberate Self-Harm in Adolescents: An Open Label Pilot Study Completed NCT01111734 Phase 1 fMRI
44 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Recruiting NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
45 Effect of Fish Oil vs. Placebo on Subjective Effects of Alcohol in Healthy Humans Recruiting NCT03010917 Phase 1 Fish Oil with ethanol and placebo ethanol infusions;Placebo with ethanol and placebo ethanol infusions
46 Dialectical Behavioral Therapy for Patients With Borderline Personality Disorder Unknown status NCT00252031
47 A Sham-controlled Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Patients Unknown status NCT01602497
48 Event Related Potentials in Borderline Personality Disorder and Major Depression Unknown status NCT01469663
49 Effects of Dialectical Behavioral Therapy and Escitalopram on Impulsive Aggression, Affective Instability and Cognitive Processing in Borderline Personality Disorder Unknown status NCT00255554 Escitalopram
50 Emotional Reaction of Patients With Borderline Personality Disorder (BPD)on Stimuli Connected to Self-injury - A Comparison Between Patients With BPD and a Healthy Control Group. Unknown status NCT03149926

Search NIH Clinical Center for Borderline Personality Disorder

Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

Anatomical Context for Borderline Personality Disorder

MalaCards organs/tissues related to Borderline Personality Disorder:

41
Brain, Testes, Amygdala, Cortex, Skin, Pituitary, Eye

Publications for Borderline Personality Disorder

Articles related to Borderline Personality Disorder:

(show top 50) (show all 5886)
# Title Authors PMID Year
1
Association analysis between gene variants of the tyrosine hydroxylase and the serotonin transporter in borderline personality disorder. 9 38
20146650 2010
2
In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. 9 38
19523495 2009
3
Interaction between gene variants of the serotonin transporter promoter region (5-HTTLPR) and catechol O-methyltransferase (COMT) in borderline personality disorder. 9 38
18756498 2009
4
Serotonin transporter polymorphism and fluoxetine effect on impulsiveness and aggression in borderline personality disorder. 9 38
17597424 2007
5
Association between the serotonin transporter gene and personality traits in borderline personality disorder patients evaluated with Zuckerman-Zuhlman Personality Questionnaire (ZKPQ). 9 38
18004675 2007
6
Monoamine oxidase a gene is associated with borderline personality disorder. 9 38
17417058 2007
7
[Personality disorders in a nonclinical sample of adolescents]. 9 38
12506264 2002
8
Out of control? Acting out anger is associated with deficient prefrontal emotional action control in male patients with borderline personality disorder. 38
30553826 2019
9
Personality disorders and physical comorbidities: a complex relationship. 38
31219842 2019
10
DSM Borderline Criterion Function Across Age-Groups: A Cross-Sectional Mixed-Method Study. 38
30003799 2019
11
Violent offending in borderline personality disorder and attention deficit/hyperactivity disorder. 38
30844407 2019
12
The link between rejection sensitivity and borderline personality disorder: A systematic review and meta-analysis. 38
30900278 2019
13
Evaluating "mentalizing positive affect" as an intervention for enhancing positive affectivity in borderline personality disorder using a single-case multiple-baseline design. 38
31393151 2019
14
Heart rate variability during a cognitive reappraisal task in female patients with borderline personality disorder: the role of comorbid posttraumatic stress disorder and dissociation. 38
30198447 2019
15
Stigma, Emotion Appraisal, and the Family Environment as Predictors of Carer Burden for Relatives of Individuals Who Meet the Diagnostic Criteria for Borderline Personality Disorder. 38
30307828 2019
16
The experiences of people with borderline personality disorder admitted to acute psychiatric inpatient wards: a meta-synthesis. 38
28686468 2019
17
Ruminative responses to interpersonal precipitants mediate borderline personality disorder features' effects on distress reactivity and recovery in daily life. 38
31392728 2019
18
Resting-state functional connectivity after hydrocortisone administration in patients with post-traumatic stress disorder and borderline personality disorder. 38
31262544 2019
19
Individualized treatment response prediction of dialectical behavior therapy for borderline personality disorder using multimodal magnetic resonance imaging. 38
31414575 2019
20
Relations among maternal withdrawal in infancy, borderline features, suicidality/self-injury, and adult hippocampal volume: A 30-year longitudinal study. 38
31381974 2019
21
Parent Emotion Socialization and Child Emotional Vulnerability as Predictors of Borderline Personality Features. 38
31388862 2019
22
Barriers and facilitators to the implementation of a stepped care intervention for personality disorder in mental health services. 38
31411004 2019
23
Homicidal Ideation and Forensic Psychopathology: Evidence From the 2016 Nationwide Emergency Department Sample (NEDS). 38
31404481 2019
24
Does an adapted Dialectical Behaviour Therapy skills training programme result in positive outcomes for participants with a dual diagnosis? A mixed methods study. 38
31412957 2019
25
Suicide ideation and attempts in obsessive-compulsive disorder. 38
31046037 2019
26
Cognitive and Behavioral Differentiation of Those With Borderline Personality Disorder and Bipolar Disorder. 38
31283725 2019
27
Circadian rest-activity patterns in bipolar disorder and borderline personality disorder. 38
31431612 2019
28
Screening for Bipolar Disorder and Finding Borderline Personality Disorder: A Replication and Extension. 38
30036171 2019
29
The 24-year course of major depression in patients with borderline personality disorder and personality-disordered comparison subjects. 38
31400625 2019
30
Construct Validity of the McLean Screening Instrument for Borderline Personality Disorder in Two Singaporean Samples. 38
29949444 2019
31
A meta-analysis of treatment as usual for borderline personality disorder. 38
31414854 2019
32
Cross-Domain Assessment of Distress Intolerance: Associations With Borderline Personality Disorder Features. 38
30307823 2019
33
Respiratory Sinus Arrhythmia Mediates Links Between Borderline Personality Disorder Symptoms and Both Aggressive and Violent Behavior. 38
30307825 2019
34
Staff and client perspectives of the Open Borders programme for people with borderline personality disorder. 38
31081282 2019
35
Neurophysiological activity following rewards and losses among female adolescents and young adults with borderline personality disorder. 38
31318241 2019
36
Neurocircuitry associated with symptom dimensions at baseline and with change in borderline personality disorder. 38
31302291 2019
37
Predictors of short- and long-term recurrence of suicidal behavior in borderline personality disorder. 38
31155713 2019
38
A short screening tool for borderline personality disorder (Short-Bord): Validated by Rasch analysis. 38
31415930 2019
39
Are self-report cognitive empathy ratings valid proxies for cognitive empathy ability? Negligible meta-analytic relations with behavioral task performance. 38
31120296 2019
40
Borderline personality disorder and emotion dysregulation. 38
31169118 2019
41
Toward an animal model of borderline personality disorder. 38
31201478 2019
42
Whole-brain functional connectivity during script-driven aggression in borderline personality disorder. 38
30885789 2019
43
Changes in facial emotion expression during a psychotherapeutic intervention for patients with borderline personality disorder. 38
31071663 2019
44
[Erratum to: Oxytocin and maltreatment potential : Influence of maternal depression, borderline personality disorder and experience of early childhood maltreatment]. 38
31089782 2019
45
Precursors of the emotional cascade model of borderline personality disorder: The role of neuroticism, childhood emotional vulnerability, and parental invalidation. 38
30896201 2019
46
Borderline personality disorder and its association with bipolar spectrum and binge eating disorder in college students from South India. 38
31302438 2019
47
Mixed-methods evaluation of an educational intervention to change mental health nurses' attitudes to people diagnosed with borderline personality disorder. 38
30830704 2019
48
Associations of positive and negative emotions with ego-resiliency and quality of life in borderline personality disorder: A daily diary study. 38
31318235 2019
49
Impulse control under emotion processing: an fMRI investigation in borderline personality disorder compared to non-patients and cluster-C personality disorder patients. 38
31321661 2019
50
The weirdness of having a bunch of other minds like yours in the room: The lived experiences of mentalization-based therapy for borderline personality disorder. 38
31301159 2019

Variations for Borderline Personality Disorder

Expression for Borderline Personality Disorder

Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for Borderline Personality Disorder

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 PRL NR3C1 HTR2C HTR2A HTR1B HTR1A
2 12.03 HTR1B HTR1A BDNF
3
Show member pathways
11.98 HTR2C HTR2A AVPR1A
4 11.91 TPH1 SLC6A4 NR3C1 MAOA HTR2A HTR1A
5
Show member pathways
11.66 HTR2C HTR2A HTR1B HTR1A
6 11.56 TPH1 SLC6A4 MAOA HTR2C HTR2A HTR1B
7 11.49 PRL NR3C1 FKBP5
8
Show member pathways
10.96 SLC6A4 MAOA COMT
9 10.8 HTR2C HTR2A
10
Show member pathways
10.78 TPH1 MAOA COMT
11
Show member pathways
10.65 MAOA COMT
12 10.61 TPH1 SLC6A4 MAOA HTR2C HTR2A HTR1B
13 10.6 MAOA COMT

GO Terms for Borderline Personality Disorder

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.73 SLC6A4 HTR2C HTR2A HTR1B HTR1A AVPR1A
2 integral component of presynaptic membrane GO:0099056 9.33 SLC6A4 HTR2A HTR1B
3 dendrite GO:0030425 9.1 HTR2C HTR2A HTR1B HTR1A COMT BDNF
4 serotonergic synapse GO:0099154 8.96 SLC6A4 HTR1B

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 PRL HTR2A HTR1A AVPR1A
2 chemical synaptic transmission GO:0007268 9.83 HTR2C HTR2A HTR1B HTR1A
3 memory GO:0007613 9.72 SLC6A4 HTR2A BDNF
4 positive regulation of fat cell differentiation GO:0045600 9.67 TPH1 HTR2C HTR2A
5 feeding behavior GO:0007631 9.62 HTR2C HTR1B
6 regulation of dopamine secretion GO:0014059 9.62 HTR2A HTR1B
7 positive regulation of vasoconstriction GO:0045907 9.61 HTR2A AVPR1A
8 behavioral fear response GO:0001662 9.61 HTR2C HTR1A
9 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.61 HTR2A HTR1B HTR1A
10 bone remodeling GO:0046849 9.6 TPH1 HTR1B
11 circadian rhythm GO:0007623 9.59 TPH1 SLC6A4
12 regulation of behavior GO:0050795 9.58 HTR1B HTR1A
13 neurotransmitter catabolic process GO:0042135 9.58 MAOA COMT
14 catecholamine metabolic process GO:0006584 9.57 MAOA COMT
15 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.56 HTR2A HTR1B
16 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.56 HTR2C HTR2A HTR1B HTR1A
17 dopamine catabolic process GO:0042420 9.54 MAOA COMT
18 activation of phospholipase C activity GO:0007202 9.54 HTR2A BDNF AVPR1A
19 sperm ejaculation GO:0042713 9.51 SLC6A4 AVPR1A
20 vasoconstriction GO:0042310 9.5 SLC6A4 HTR1B HTR1A
21 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.48 HTR2C HTR2A
22 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.46 HTR1B HTR1A
23 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.4 HTR2C HTR2A
24 response to drug GO:0042493 9.35 SLC6A4 HTR2C HTR2A HTR1B COMT
25 serotonin receptor signaling pathway GO:0007210 9.33 HTR2C HTR2A HTR1A
26 behavior GO:0007610 8.92 HTR2C HTR2A HTR1B HTR1A
27 signal transduction GO:0007165 10.11 NR3C1 HTR2C HTR2A HTR1B HTR1A AVPR1A
28 G protein-coupled receptor signaling pathway GO:0007186 10.04 HTR2C HTR2A HTR1B HTR1A AVPR1A

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.77 HTR2C HTR2A HTR1B HTR1A AVPR1A
2 drug binding GO:0008144 9.5 HTR2C HTR2A HTR1B
3 neurotransmitter receptor activity GO:0030594 9.46 HTR2C HTR2A HTR1B HTR1A
4 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.26 HTR2C HTR2A
5 G protein-coupled serotonin receptor activity GO:0004993 9.26 HTR2C HTR2A HTR1B HTR1A
6 serotonin binding GO:0051378 9.02 SLC6A4 HTR2C HTR2A HTR1B HTR1A

Sources for Borderline Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....